Part II: Dose expansion - this stage is to further evaluate the preliminary anti-tumor effects of BGB-3111 in Chinese subjects with follicular lymphoma (FL) or marginal zone lymphoma (MZL), approximately 20 subjects with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) will be enrolled. The recommended Phase 2 dose will be used in the Part II.